A new Lancet Oncology Commission highlights a growing "human crisis" in cancer care. Despite advances in treatment and ...

Longer-term trial results show Voranigo may help control grade 2 IDH-mutated glioma after surgery for those who can delay ...

Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation ...

"These longer-term results from the INDIGO trial build upon VORANIGO's previously demonstrated clinical benefits and ...

Vorasidenib significantly improved median progression-free survival and time to next intervention in IDH-mutant grade 2 ...

While AI advancements like 3D tumor auto-segmentation and radiation therapy planning have been FDA-approved for adult oncology, pediatric standards were lacking. The AI-RAPNO policy and its companion ...

On Oct 8, 2025, a new law was introduced in British Columbia, Canada, that, if passed, will take action against e-cigarette ...

Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The ...

News involving the treatment of multiple myeloma this year was highlighted by talk of a potential cure with a single infusion ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

Last week, Lancet Oncology released a special report, "Future Cancer Research Priorities in the USA: A Lancet Oncology Commission." As co-author of this report, I joined fellow cancer research experts ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...